Iohexol (300 mg Iodine/mL), 2.4 g Iodine/8 ml, Total Volume 8 ml in 10 ml syringe, 5-count syring...

FDA Recall #D-0086-2023 — Class I — December 1, 2022

Recall #D-0086-2023 Date: December 1, 2022 Classification: Class I Status: Terminated

Product Description

Iohexol (300 mg Iodine/mL), 2.4 g Iodine/8 ml, Total Volume 8 ml in 10 ml syringe, 5-count syringes packaged in a bag labeled as Omnipaque (iohexol) 300 mg I/mL, 2.4g Iodine/8 mL in a 10 mL syringe, Compounded with GE Healthcare product, Each mL contains (647 mg) of iohexol as 300 mg of organically bound iodine, 1.21 mg tromethamine, and 0.1 mg edetate calcium disodium, For Injection or oral use; Rx Only, BayCare Central Pharmacy, 7802 Telecom Parkway, Temple Terrace, FL 33637.

Reason for Recall

Labeling: Label Error on Declared Strength: syringes mislabeled as 300 mg iodine/mL contained product 350 mg iodine/mL

Recalling Firm

BayCare Integrated Service Center, LLC /dba BayCare Central Pharmacy — Temple Terrace, FL

Classification

Class I — Reasonable probability of serious adverse health consequences or death.

Product Type

Drugs

Product Quantity

250 syringes

Distribution

BayCare Health System hospitals in FL

Code Information

Lot: IOHE2.420221128, Exp. 12/7/2022

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated